Clindamycin and Belzutifan: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 1, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Belzutifan
Clindamycin
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Let's talk about taking Welireg (belzutifan) along with the antibiotic clindamycin. Belzutifan can speed up an enzyme in your body (called CYP3A4) that breaks down many medicines. Since your body clears clindamycin partly through this same enzyme, belzutifan could make your body get rid of the antibiotic a little faster. In theory, that might make the antibiotic less effective at fighting your infection.
I want to be honest: this is a theoretical concern, not something proven with these two drugs. The good news is your care team can watch how your infection is responding and adjust things if needed. Please don't stop either medicine on your own, just check in with your doctor or pharmacist.
Mechanism: Belzutifan is a CYP3A4 inducer; clindamycin is partly metabolized by CYP3A4. Enzyme induction may increase clindamycin clearance, lowering exposure (AUC/Cmax) and potentially reducing antimicrobial efficacy.
- Direction: reduced clindamycin effect (induction, not a prodrug scenario).
- Magnitude: not established for clindamycin; belzutifan reduced midazolam AUC by ~40% (up to ~70% in dual UGT2B17/CYP2C19 poor metabolizers).
- Evidence: theoretical.
- Onset: unspecified (induction is typically delayed).
Management: Monitor clinical response to clindamycin; consider dose optimization or an alternative antibiotic if inadequate response. Effect may be more pronounced in dual poor metabolizers.
What happens
Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI
Interaction Deep Dive
Belzutifan should not be given together with sensitive CYP3A4 substrates when even a small drop in the substrate's concentration could cause it to fail therapeutically. When such coadministration is unavoidable, raise the dose of the sensitive CYP3A4 substrate as required. Giving belzutifan alongside CYP3A4 substrates may lower the exposure of CYP3A4 substrates with an NTI, potentially diminishing their effectiveness. This effect may be greater in patients who are poor metabolizers for both UGT2B17 and CYP2C19. When belzutifan was administered with midazolam (a sensitive CYP3A4 substrate), the midazolam AUC fell by 40% and the Cmax by 34%. In patients with elevated belzutifan concentrations (for example, dual poor metabolizers), midazolam AUC is projected to drop by as much as 70%1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism by belzutifan
How to manage this interaction
Here is how a care team typically handles this pairing:
- Keep taking both as prescribed unless your doctor tells you otherwise.
- Your team may watch how your infection responds to the antibiotic more closely.
- If clindamycin does not seem to be working well enough, the dose may be adjusted and individualized, or an alternative antibiotic may be chosen.
What to raise with your pharmacist or prescriber: tell them you take Welireg, and report if your infection symptoms are not improving as expected. That way they can tailor your treatment.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) Giving belzutifan 120 mg once daily together with midazolam (a sensitive CYP3A4 substrate) reduced the midazolam AUC by 40% and the Cmax by 34%. In patients with higher belzutifan concentrations (for example, dual poor metabolizers), the midazolam AUC is projected to fall by as much as 70% 1.
Common questions
Can I take Clindamycin and Belzutifan together?
Belzutifan may speed up how your body clears clindamycin, which could make the antibiotic work less well; this is theoretical, so keep taking both and let your care team monitor and adjust your treatment if needed. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Clindamycin and Belzutifan interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Clindamycin and Belzutifan interaction managed?
Here is how a care team typically handles this pairing: Keep taking both as prescribed unless your doctor tells you otherwise. Your team may watch how your infection responds to the antibiotic more closely. If clindamycin does not seem to be working well enough, the dose may be adjusted and individualized, or an alternative antibiotic may be chosen. What to raise with your pharmacist or prescriber… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Clindamycin or Belzutifan need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: WELIREG(R) oral tablets, belzutifan oral tablets. Merck Sharp & Dohme LLC (per manufacturer), Rahway, NJ, 2025. DailyMed
Keep reading about Belzutifan
Keep reading about Clindamycin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist